Aspen Pharmacare Holdings, Africas largest drugmaker, led by South African pharma tycoon Stephen Saad, has reached a settlement worth R500 million 28.8 million with an overseas contract manufacturing client after a dispute over mRNA drug production .
Aspen confirmed the agreement in a statement to shareholders on Friday, ending months of uncertainty surrounding the issue that had weighed on its stock earlier this year. It said the counterparty will pay EUR25 million 29 million by Dec. 1, 2025, in full and final settlement.
The disagreement stemmed from a manufacturing and technology agreement involving mRNA products, according to Aspens previous filings. The matter had been cited by analysts as one of the key reasons for investor caution around the stock.